Riyadh biotech summit to draw global leaders in September 2026

Saudi Arabia will host the fourth Riyadh Global Medical Biotechnology Summit from Sept. 14-16, 2026, bringing together more than 100 speakers and delegates from 70+ countries. The event is designed to support the kingdom’s biotech strategy by advancing regulation, manufacturing, investment and talent infrastructure.

Why it matters: - Saudi Arabia is using RGMBS 2026 to advance its national biotechnology strategy and position Riyadh as a regional and global hub for biotech innovation, investment and talent. - The summit is built around the full biotech value chain, which means progress in research, regulation, manufacturing and commercialization is meant to move together. - The strategy’s long-term economic target is $34.6 billion in non-oil biotech GDP by 2040.

What happened: - The fourth Riyadh Global Medical Biotechnology Summit will take place in Riyadh from Sept. 14-16, 2026. - More than 100 local and international speakers are scheduled to participate. - Organizers expect more than 15,000 visitors, 200 biotech and health brands, and 80+ government and industry exhibitors. - Delegations from 70+ countries are expected to attend. - The three-day event is expected to produce 65+ agreements and memorandums of understanding. - Registration is open for delegates, exhibitors and industry partners. - Full agenda and event details are available in the official summit information.

The details: - The summit will focus on six themes: artificial intelligence in biotechnology, multi-omics and localization, biotech investment, immunology, bioengineering and synthetic biology, and biotechnology talent development. - The scientific program spans population-scale genomics, AI-driven drug discovery, domestic biomanufacturing, regulatory science, commercialization and investment. - International attendees will see Saudi Arabia’s regulatory framework, manufacturing infrastructure and translational research capabilities across the biotech value chain. - The summit is organized under the supervision of the National Guard through its Health Affairs arm. - King Abdullah International Medical Research Center and King Saud bin Abdulaziz University for Health Sciences are hosting the event. - The Ministry of Investment, Invest Saudi and the Saudi Data and Artificial Intelligence Authority are the main strategic partners. - The summit is designed to reinforce the kingdom’s biotech ecosystem by linking discovery research, cGMP manufacturing and regulatory infrastructure. - Bandar Alknawy said this year’s theme is “laying the foundation for biotech excellence” and that the program emphasizes structural depth over broad global reach. - Alknawy also pointed to collaborations with Harvard in translational oncology, AstraZeneca in gene therapy and Peking University in drug discovery.

Between the lines: - Saudi Arabia is signaling that biotech growth will depend on institution building, not just headline partnerships or event scale. - The emphasis on regulation, manufacturing and talent suggests the kingdom wants to compete for more than conference attention; it wants durable industrial capacity. - The summit’s mix of science, policy and dealmaking points to a push to turn research relationships into commercial activity.

What's next: - Organizers will publish the full scientific agenda, speaker lineup and event updates ahead of the September summit. - Delegates and partners can continue registering at official summit information. - The event will likely be watched as a checkpoint for how quickly Saudi Arabia can translate its biotech strategy into partnerships, investment and infrastructure.